08.04.2016
Evonik Industries AG DE000EVNK013
DGAP-News: Evonik Industries AG: Evonik acquires French biotech company
DGAP-News: Evonik Industries AG / Key word(s): Takeover
Evonik Industries AG: Evonik acquires French biotech company
08.04.2016 / 09:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Evonik acquires French biotech company
- Evonik acquires strength in the area of sustainably developed
ingredients for cosmetics
- Alkion Biopharma SAS extracts cosmetic actives from plant biomass
On April 6, 2016, Evonik Industries concluded a purchase agreement to take
over the start-up Alkion Biopharma SAS, headquartered in Evry (France). The
transaction is due to be completed in April. Alkion specializes in the
development of biotechnological active ingredients for the cosmetics
industry and was founded as a spin-off of the Imperial College London in
2011. Evonik is purchasing this company to expand the portfolio of the
Personal Care Business Line in the area of active ingredients. The purchase
price has not been disclosed.
"Thanks to its formulation and application expertise, Evonik enjoys an
excellent reputation in the cosmetics industry. We are resolutely
continuing along this path with the acquisition of Alkion," said Dr. Tammo
Boinowitz, head of the Personal Care Business Line at Evonik. By taking
over the French biotech company, Evonik is strengthening its portfolio of
specialty active ingredients. "This allows us to offer customers product
concepts to set themselves apart from competitors," said Boinowitz. Evonik
is now able to offer its customers highly effective customized plant-based
active ingredients that live up to their product claims.
Alkion Biopharma SAS is one of the leading manufacturers of
biotechnologically developed cosmetic active ingredients. The company has
developed methods for cultivating plant biomass under laboratory conditions
and obtaining extracts from this with an exceptionally high yield of
complex ingredients. The entire process takes place without altering the
plant genome. "We are simply reinforcing the strength of nature. This
results in unique, innovative cosmetic actives," said Dr. Franck Michoux,
founder and CEO of Alkion. He believes the affiliation with Evonik will
provide outstanding opportunities for successful marketing of this
technology.
Company information
Evonik, the creative industrial group from Germany, is one of the world
leaders in specialty chemicals. Profitable growth and a sustained increase
in the value of the company form the heart of Evonik's corporate strategy.
Its activities focus on the key megatrends health, nutrition, resource
efficiency and globalization. Evonik benefits specifically from its
innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2015
more than 33,500 employees generated sales of around EUR13.5 billion and an
operating profit (adjusted EBITDA) of about EUR2.47 billion.
About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and
contributes to fulfilling basic human needs. That includes applications for
everyday consumer goods as well as animal nutrition and health care. This
segment employed about 7,000 employees, and generated sales of around
EUR4.9 billion in 2015.
Disclaimer
In so far as forecasts or expectations are expressed in this Investor
Relations News or where our statements concern the future, these forecasts,
expectations or statements may involve known or unknown risks and
uncertainties. Actual results or developments may vary, depending on
changes in the operating environment. Neither Evonik Industries AG nor its
group companies assume an obligation to update the forecasts, expectations
or statements contained in this release.
Contact:
Tim Lange
Head of Investor Relations
+49 201 177-3150
[email protected]
Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
Telefax +49 201 177-3475
www.evonik.com
Supervisory Board
Dr. Werner Müller, Chairman
Executive Board
Dr. Klaus Engel, Chairman
Dr. Ralph Sven Kaufmann
Christian Kullmann
Thomas Wessel
Ute Wolf
Registered office Essen
Registered court
Essen local court
Commercial registry B 19474
VAT ID no. DE 811160003
---------------------------------------------------------------------------
08.04.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone: +49 (0) 201 177-01
Fax: +49 (0) 201 177-3475
E-mail: [email protected]
Internet: www.evonik.com
ISIN: DE000EVNK013, XS0911405784
WKN: EVNK01, A1TM7T
Indices: MDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Hamburg, Hanover, Munich,
Stuttgart; Terminbörse EUREX; Luxemburg
End of News DGAP News Service
---------------------------------------------------------------------------
452109 08.04.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evonik Industries AG ISIN: DE000EVNK013 können Sie bei EQS abrufen
Chemie , EVNK01 , EVK , XETR:EVK